Mangalam Drugs and Organics Ltd banner

Mangalam Drugs and Organics Ltd
NSE:MANGALAM

Watchlist Manager
Mangalam Drugs and Organics Ltd Logo
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
Watchlist
Price: 29.92 INR 2.08% Market Closed
Market Cap: ₹473.6m

Multiples-Based Value

The Multiples-Based Value of one MANGALAM stock under the Base Case scenario is hidden INR. Compared to the current market price of 29.92 INR, Mangalam Drugs and Organics Ltd is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MANGALAM Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

MANGALAM Competitors Multiples
Mangalam Drugs and Organics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
473.6m INR 0.2 -1.5 128.5 -7.6
US
Eli Lilly and Co
NYSE:LLY
847.5B USD 13 41.1 27.7 29.6
US
Johnson & Johnson
NYSE:JNJ
576.1B USD 6.1 21.5 14.9 18.4
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4 19.3 11.5 12.9
US
Merck & Co Inc
NYSE:MRK
294.3B USD 4.5 16.1 10 12.1
CH
Novartis AG
SIX:NOVN
229.3B CHF 5.2 21.1 13.1 16.8
UK
AstraZeneca PLC
LSE:AZN
214.5B GBP 5.1 29.2 16.2 22.8
IE
Endo International PLC
LSE:0Y5F
237.1B USD 102.3 -81.1 375.3 941.3
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK 3.3 9.9 7.4 8.7
US
Pfizer Inc
NYSE:PFE
156.8B USD 2.5 20.2 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
119.6B USD 2.5 17 7.2 8.8
P/E Multiple
Earnings Growth PEG
IN
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
Average P/E: 21.7
Negative Multiple: -1.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
41.1
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
21.5
7%
3.1
CH
Roche Holding AG
SIX:ROG
19.3
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.1
14%
1.2
CH
Novartis AG
SIX:NOVN
21.1
14%
1.5
UK
AstraZeneca PLC
LSE:AZN
29.2
26%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -81.1 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.9
1%
9.9
US
Pfizer Inc
NYSE:PFE
20.2
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
Average EV/EBITDA: 56.3
128.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
27.7
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.5
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10
3%
3.3
CH
Novartis AG
SIX:NOVN
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
16.2
13%
1.2
IE
E
Endo International PLC
LSE:0Y5F
375.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.4
1%
7.4
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.2
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Mangalam Drugs and Organics Ltd
NSE:MANGALAM
Average EV/EBIT: 108.2
Negative Multiple: -7.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.6
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
18.4
6%
3.1
CH
Roche Holding AG
SIX:ROG
12.9
6%
2.2
US
Merck & Co Inc
NYSE:MRK
12.1
6%
2
CH
Novartis AG
SIX:NOVN
16.8
9%
1.9
UK
AstraZeneca PLC
LSE:AZN
22.8
21%
1.1
IE
E
Endo International PLC
LSE:0Y5F
941.3
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.7
2%
4.3
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett